8-K 1 h80797e8-k.txt LEXICON GENETICS INCORPORATED - SEPTEMBER 26, 2000 1 ================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): SEPTEMBER 26, 2000 LEXICON GENETICS INCORPORATED (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE 000-30111 76-0474169 (STATE OR OTHER JURISDICTION OF (COMMISSION FILE NUMBER) (I.R.S. EMPLOYER INCORPORATION OR ORGANIZATION) IDENTIFICATION NUMBER)
4000 RESEARCH FOREST DRIVE THE WOODLANDS, TEXAS 77381 (ADDRESS OF PRINCIPAL eXECUTIVE OFFICES AND ZIP CODE) (281) 364-0100 (REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE) ================================================================================ 2 ITEM 5. OTHER EVENTS We entered into a database access and license agreement with Bristol-Myers Squibb Company on September 26, 2000. Bristol-Myers Squibb will have access under the agreement to our LexVision(TM) database, which contains phenotypic information derived from our gene knockout platform. Scientists use mouse knockouts - in which genes are deleted, or "knocked out," of the mouse genome - to determine which human gene products are valid targets for the discovery and development of new medicines. Bristol-Myers Squibb will also have access to our OmniBank library of more than 90,000 mouse embryonic stem cell clones derived from our gene-trap technology. The term of the agreement is five years, although either party may terminate after three years. Under the agreement, we could receive between $15 million and $25 million in access and delivery fees, in addition to milestones and royalties on products Bristol-Myers Squibb develops using our technology. ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS (c) Exhibits
EXHIBIT NO. DESCRIPTION ----------- ----------- +10.1 -- LexVision(TM) Database and Collaboration Agreement, dated September 26, 2000, between Lexicon Genetics Incorporated and Bristol-Myers Squibb Company.
--------------------- + Confidential treatment has been requested for a portion of this exhibit. The confidential portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission. 2 3 SIGNATURES Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. LEXICON GENETICS INCORPORATED Date: October 10, 2000 By: /s/ JEFFREY L. WADE ------------------------------ Jeffrey L. Wade Executive Vice President and General Counsel 3 4 INDEX TO EXHIBITS
EXHIBIT NO. DESCRIPTION ----------- ----------- +10.1 -- LexVision(TM) Database and Collaboration Agreement, dated September 26, 2000, between Lexicon Genetics Incorporated and Bristol-Myers Squibb Company.
--------------------- + Confidential treatment has been requested for a portion of this exhibit. The confidential portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission.